ImmunoPrecise Antibodies Ltd.
IPA
$0.3918
-$0.0082-2.05%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 35.98% | 78.04% | -510.88% | -22.61% | 30.67% |
| Total Depreciation and Amortization | 1.66% | -11.55% | 19.35% | -4.32% | -11.04% |
| Total Amortization of Deferred Charges | 6.45% | -51.94% | 58.28% | -- | -- |
| Total Other Non-Cash Items | 76.32% | -102.28% | 21,345.11% | 71.79% | -94.85% |
| Change in Net Operating Assets | -193.64% | 727.77% | -119.25% | -9.76% | 52.87% |
| Cash from Operations | -23.32% | 31.61% | -294.85% | -3,609.02% | 96.79% |
| Capital Expenditure | 75.22% | 76.87% | -779.62% | 155.50% | -116.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 114.75% | -733.33% | -115.07% |
| Cash from Investing | 75.22% | 76.54% | -2,040.28% | 118.36% | -55.59% |
| Total Debt Issued | -43.82% | -- | -- | -- | -- |
| Total Debt Repaid | -3.30% | -30.46% | 6.21% | -3.87% | 23.46% |
| Issuance of Common Stock | 106.92% | -65.54% | 52.41% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -23.04% | 137.90% | 82.29% | 298.86% | 24.80% |
| Foreign Exchange rate Adjustments | 8.89% | -35.05% | -162.12% | 363.98% | 82.97% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -183.54% | 116.43% | -1,576.06% | 126.24% | 55.15% |
